tirzepatide and fda Wins Approval for Weight Loss Sandoz Moves Closer to Generic

Recent studies report visual side effects, which have the eye care world wondering if GLP-1s are a little too good to be true.

A careful but direct response to a public critiquelaying out the data on statins and GLP-1, a conspicuous omission, and what scientific integrity demands when evidence gets uncomfortable...

Results Each propensity-score matched group constituted 3424 patients, 45% women, 21% had a history of cardiovascular disease, and 13.9% were treated with sodium-glucose cotransporter-2 inhibitors at baseline

No injections required!

The expansion of GLP-1 drug efficacy evidence in 2024, a concise review by Daniel Drucker, a pioneer of the field | 28 comments on LinkedIn

Materials and methods The effects of long-term exposures to tirzepatide, a novel dual GIP/GLP-1 receptor agonist, on neurotoxicity and behavioral changes in the D-galactose/aluminium chloride (D-gal/AlCl3)-induced rats' AD-like pathological model were evaluated